Acta Neuropathologica

, Volume 125, Issue 4, pp 581–593 | Cite as

Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation

  • Lea Tenenholz Grinberg
  • Xuehua Wang
  • Chao Wang
  • Peter Dongmin Sohn
  • Panos Theofilas
  • Manu Sidhu
  • John Benjamin Arevalo
  • Helmut Heinsen
  • Eric J. Huang
  • Howard Rosen
  • Bruce L. Miller
  • Li Gan
  • William W. Seeley
Original Paper

Abstract

Post-translational modifications play a key role in tau protein aggregation and related neurodegeneration. Because hyperphosphorylation alone does not necessarily cause tau aggregation, other post-translational modifications have been recently explored. Tau acetylation promotes aggregation and inhibits tau’s ability to stabilize microtubules. Recent studies have shown co-localization of acetylated and phosphorylated tau in AD and some 4R tauopathies. We developed a novel monoclonal antibody against acetylated tau at lysine residue 274, which recognizes both 3R and 4R tau, and used immunohistochemistry and immunofluorescence to probe 22 cases, including AD and another eight familial or sporadic tauopathies. Acetylated tau was identified in all tauopathies except argyrophilic grain disease (AGD). AGD is an age-associated, common but atypical 4R tauopathy, not always associated with clinical progression. Pathologically, AGD is characterized by neuropil grains, pre-neurofibrillary tangles, and oligodendroglial coiled bodies, all recognized by phospho-tau antibodies. The lack of acetylated tau in these inclusions suggests that AGD represents a distinctive tauopathy. Our data converge with previous findings to raise the hypothesis that AGD could play a protective role against the spread of AD-related tau pathology. Tau acetylation as a key modification for the propagation tau toxicity deserves further investigation.

Keywords

Tau Pathology Autopsy Acetylation Immunohistochemistry Human 

Supplementary material

401_2013_1080_MOESM1_ESM.tif (4 mb)
Online resource 1 Antigen competition assay. a inferior temporal cortex of an AD case (case # 3) after immunohistochemistry with MAb 359. Note the plaques and tangles in dark brown. b higher magnification of (a). The plaques and tangles can be visualized in detail. c a parallel slide to (a) after immunohistochemistry with MAb 359 pre-incubated with the antigen used for its generation. All the other reaction steps were the same as in (a). Note that the reaction was negative, supporting MAb 359 specificity against tau acetylated at position 274. d higher magnification of (b). Scale bars represent 500 μm in a and c, and 100 μm in b and d. (TIFF 4699 kb)
401_2013_1080_MOESM2_ESM.tif (2.2 mb)
Online resource 2 Inferior temporal cortex of Pick’s disease (case 18) after immunofluorescence with CP-13 (a) and MAb 359 (b) antibodies. Pick bodies are both phosphorylated (a) and acetylated (b). Most of the inclusions have both changes and the processes are mainly phosphorylated only (c). Scale bar represents 50 μm (TIFF 4050 kb)
401_2013_1080_MOESM3_ESM.tif (4.6 mb)
Online resource 3 Across all tauopathies, neuronal processes were rarely ac-tau positive. This figure shows parallel sections of the hippocampal dentate gyrus granule cell (top of the figure) and molecular layers (bottom of the figure) in Alzheimer’s disease (case 3) immunostained with (a) CP-13 and (b) MAb 359. Note the strong phospho-tau positivity and absent ac-tau positivity in the external portion of the molecular layer. The dentate gyrus molecular layer contains abundant axons and dendrites. This figure demonstrates the remarkable discrepancy between phosphor-tau and ac-tau changes in neuronal processes. The arrow in b shows an acetylated tau-positive neurofibrillary tangle as an internal positive control. (TIFF 2268 kb)

References

  1. 1.
    Ahmed Z, Doherty KM, Silveira-Moriyama L, Bandopadhyay R, Lashley T, Mamais A et al (2011) Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol 122:28–415CrossRefGoogle Scholar
  2. 2.
    Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672PubMedCrossRefGoogle Scholar
  3. 3.
    Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC et al (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55:326–335PubMedCrossRefGoogle Scholar
  4. 4.
    Braak H, Braak E (1989) Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 15:13–26PubMedCrossRefGoogle Scholar
  5. 5.
    Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969PubMedCrossRefGoogle Scholar
  6. 6.
    Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33:95–130PubMedCrossRefGoogle Scholar
  7. 7.
    Buee L, Delacourte A (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol 9:681–693PubMedCrossRefGoogle Scholar
  8. 8.
    Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769–776PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252PubMedCrossRefGoogle Scholar
  11. 11.
    Duyckaerts C (2004) Looking for the link between plaques and tangles. Neurobiol Aging 25:735–739PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrer I, Barrachina M, Tolnay M, Rey MJ, Vidal N, M Carmona et al (2003) Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol 13:62–78PubMedCrossRefGoogle Scholar
  13. 13.
    Ferrer I, Santpere G, van Leeuwen FW (2008) Argyrophilic grain disease. Brain 131:1416–1432PubMedCrossRefGoogle Scholar
  14. 14.
    Giannakopoulos P, Gold G, Kovari E, von Gunten A, Imhof A, Bouras C et al (2007) Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 113:1–12PubMedCrossRefGoogle Scholar
  15. 15.
    Goedert M (2001) The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev 11:343–351PubMedCrossRefGoogle Scholar
  16. 16.
    Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526PubMedCrossRefGoogle Scholar
  17. 17.
    Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8:393–399PubMedGoogle Scholar
  18. 18.
    Goode BL, Denis PE, Panda D, Radeke MJ, Miller HP, L Wilson et al (1997) Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol Biol Cell 8:353–365PubMedGoogle Scholar
  19. 19.
    Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer’s disease brain using nanoelectrospray mass spectrometry. J Neurochem 71:2465–2476PubMedCrossRefGoogle Scholar
  20. 20.
    Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH et al (2004) Clinicopathological correlates in frontotemporal dementia. Ann Neurol 56:399–406PubMedCrossRefGoogle Scholar
  21. 21.
    Ilieva EV, Kichev A, Naudi A, Ferrer I, Pamplona R, Portero-Otin M (2011) Mitochondrial dysfunction and oxidative and endoplasmic reticulum stress in argyrophilic grain disease. J Neuropathol Exp Neurol 70:253–263PubMedCrossRefGoogle Scholar
  22. 22.
    Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM et al (2012) Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135:807–818PubMedCrossRefGoogle Scholar
  23. 23.
    Jicha GA, Petersen RC, Knopman DS, Boeve BF, Smith GE, Geda YE et al (2006) Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol 65:602–609PubMedCrossRefGoogle Scholar
  24. 24.
    Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ et al (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62:1087–1095PubMedGoogle Scholar
  25. 25.
    Kovacs GG, Majtenyi K, Spina S, Murrell JR, Gelpi E, Hoftberger R et al (2008) White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:963–975PubMedCrossRefGoogle Scholar
  26. 26.
    Lee G, Neve RL, Kosik KS (1989) The microtubule binding domain of tau protein. Neuron 2:1615–1624PubMedCrossRefGoogle Scholar
  27. 27.
    Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2:a006247PubMedGoogle Scholar
  28. 28.
    Maurage CA, Sergeant N, Schraen-Maschke S, Lebert F, Ruchoux MM, Sablonniere B et al (2003) Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathol 106:575–583PubMedCrossRefGoogle Scholar
  29. 29.
    Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953–966PubMedCrossRefGoogle Scholar
  30. 30.
    Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF et al (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672PubMedCrossRefGoogle Scholar
  31. 31.
    Steuerwald GM, Baumann TP, Taylor KI, Mittag M, Adams H, Tolnay M et al (2007) Clinical characteristics of dementia associated with argyrophilic grain disease. Dement Geriatr Cogn Disord 24:229–234PubMedCrossRefGoogle Scholar
  32. 32.
    Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Griffin WS et al (2005) The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer’s disease-related pathology. Neuropathol Appl Neurobiol 31:270–279PubMedCrossRefGoogle Scholar
  33. 33.
    Tolnay M, Clavaguera F (2004) Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 24:269–283PubMedCrossRefGoogle Scholar
  34. 34.
    Tolnay M, Schwietert M, Monsch AU, Staehelin HB, Langui D, Probst A (1997) Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathol 94:353–358PubMedCrossRefGoogle Scholar
  35. 35.
    Tolnay M, Sergeant N, Ghestem A, Chalbot S, De Vos RA, Jansen Steur EN et al (2002) Argyrophilic grain disease and Alzheimer’s disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol 104:425–434PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Lea Tenenholz Grinberg
    • 1
  • Xuehua Wang
    • 1
  • Chao Wang
    • 2
  • Peter Dongmin Sohn
    • 2
    • 3
  • Panos Theofilas
    • 1
  • Manu Sidhu
    • 1
  • John Benjamin Arevalo
    • 1
  • Helmut Heinsen
    • 4
  • Eric J. Huang
    • 5
  • Howard Rosen
    • 1
  • Bruce L. Miller
    • 1
  • Li Gan
    • 2
    • 3
  • William W. Seeley
    • 1
  1. 1.Memory and Aging CenterDepartment of Neurology University of California, San FranciscoSan FranciscoUSA
  2. 2.Gladstone Institute of Neurological Disease, Department of NeurologyUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.Neuroscience Graduate ProgramUniversity of California, San FranciscoSan FranciscoUSA
  4. 4.Laboratory of Morphological Brain Research, Psychiatrics ClinicsUniversity of WuerzburgWürzburgGermany
  5. 5.Department of PathologyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations